Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWLFGO)

Drug Name
Methyltestosterone Drug Info
Synonyms Android (TN)
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [1]
Hormone deficiency 5A61.1 Approved [1]
Hot flushes GA30 Approved [1]
Hypogonadism 5A61.0 Approved [1]
Hypogonadotropic hypogonadism Approved [1]
Multiple sclerosis 8A40 Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Hypogonadism, male Investigative [1]
Cross-matching ID
PubChem CID
6010
ChEBI ID
CHEBI:27436
CAS Number
CAS 58-18-4
TTD Drug ID
DMWLFGO
INTEDE Drug ID
DR1064
ACDINA Drug ID
D00421

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [10]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [11]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [12]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [13]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [14]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [15]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [16]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [17]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [11]
Verapamil DMA7PEW Angina pectoris BA40 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [19]
Verapamil DMA7PEW Angina pectoris BA40 Approved [20]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [21]
Estrone DM5T6US Acne vulgaris ED80 Approved [22]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [23]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [24]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [25]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [26]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [27]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone DM7HUNW Hot flushes GA30 Approved [29]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [30]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [31]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [32]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [5]
Dutasteride DMQ4TJK Benign prostatic hyperplasia GA90 Approved [33]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [30]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [34]
Finasteride DMWV3TZ Baldness, male pattern Approved [5]
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [35]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Estrogen receptor (ESR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [36]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [37]
Gefitinib DM15F0X Colon adenocarcinoma Approved [38]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [39]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [40]
Liraglutide DM3FXPS Non-insulin dependent diabetes 5A11 Approved [41]
Quercetin DM3NC4M Obesity 5B81 Approved [42]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [39]
Estrone DM5T6US Acne vulgaris ED80 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Trefoil factor 1 (TFF1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [45]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [46]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [9]
Quercetin DM3NC4M Obesity 5B81 Approved [47]
Estrone DM5T6US Acne vulgaris ED80 Approved [48]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [49]
Reserpine DM6VM38 Hypertension BA00-BA04 Approved [9]
Testosterone DM7HUNW Hot flushes GA30 Approved [50]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [51]
Exemestane DM9HPW3 Hormonally-responsive breast cancer 2C60-2C65 Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prostate-specific antigen (KLK3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [53]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [54]
Selenium DM25CGV N. A. N. A. Approved [55]
Quercetin DM3NC4M Obesity 5B81 Approved [56]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [57]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [58]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [59]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [60]
Testosterone DM7HUNW Hot flushes GA30 Approved [61]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Androgen receptor (AR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [63]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [63]
Hydroxyflutamide DMGIZF5 Prostate cancer 2C82.0 Approved [63]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [64]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [65]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [66]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [67]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [68]
Selenium DM25CGV N. A. N. A. Approved [55]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [69]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein GREB1 (GREB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [53]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [70]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [49]
Testosterone DM7HUNW Hot flushes GA30 Approved [71]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [62]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [72]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [73]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [70]
Nandrolone DMFWKG1 Osteoporosis FB83.0 Approved [9]
Mestranol DMG3F94 Contraception QA21 Approved [70]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [3]
UDP-glucuronosyltransferase 2A1 (UGT2A1) DEGKRXT UD2A1_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2) OTTG0NFD S5A2_HUMAN Gene/Protein Processing [5]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Gene/Protein Processing [6]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Gene/Protein Processing [7]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Protein Interaction/Cellular Processes [8]
Protein GREB1 (GREB1) OTU6ZA26 GREB1_HUMAN Gene/Protein Processing [9]
Trefoil factor 1 (TFF1) OTCYQH4F TFF1_HUMAN Gene/Protein Processing [9]

References

1 Methyltestosterone FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6945).
3 Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):73-83.
4 Hepatic expression patterns of aryl hydrocarbon receptor, pregnane X receptor, two cytochrome P450s and five phase II metabolism genes responsive to 17alpha-methyltestosterone in rare minnow Gobiocypris rarus. Environ Toxicol Pharmacol. 2014 May;37(3):1157-68.
5 Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells. Toxicol In Vitro. 2007 Apr;21(3):502-8.
6 Development and pre-validation of an in vitro transactivation assay for detection of (anti)androgenic potential compounds using 22Rv1/MMTV cells. Reprod Toxicol. 2016 Apr;60:156-66. doi: 10.1016/j.reprotox.2016.02.006. Epub 2016 Feb 8.
7 Mixture Effects of Bisphenol A and Its Structural Analogs on Estrogen Receptor Transcriptional Activation. Toxics. 2023 Dec 4;11(12):986. doi: 10.3390/toxics11120986.
8 Cell viability and PSA secretion assays in LNCaP cells: a tiered in vitro approach to screen chemicals with a prostate-mediated effect on male reproduction within the ReProTect project. Reprod Toxicol. 2010 Aug;30(1):25-35. doi: 10.1016/j.reprotox.2010.03.008. Epub 2010 Apr 2.
9 Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals. Toxicol In Vitro. 2022 Jun;81:105348. doi: 10.1016/j.tiv.2022.105348. Epub 2022 Mar 18.
10 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
20 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
21 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
22 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
23 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
24 Drugs that may have potential CYP2B6 interactions.
25 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
26 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
27 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
28 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
29 Effects of low dose treatment of tributyltin on the regulation of estrogen receptor functions in MCF-7 cells. Toxicol Appl Pharmacol. 2013 Jun 1;269(2):176-86.
30 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
31 Propofol suppresses proliferation, migration, invasion, and tumor growth of liver cancer cells via suppressing cancer susceptibility candidate 9/phosphatase and tensin homolog/AKT serine/threonine kinase/mechanistic target of rapamycin kinase axis. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271211065972. doi: 10.1177/09603271211065972.
32 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
33 Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):129-40.
34 Molecular interactions of progesterone derivatives with 5 alpha-reductase types 1 and 2 and androgen receptors. Steroids. 2010 Jul;75(7):499-505.
35 Examining the genomic influence of skin antioxidants in vitro. Mediators Inflamm. 2010;2010.
36 Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003 Jun;144(6):2425-36. doi: 10.1210/en.2002-221054.
37 Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
38 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
39 Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
40 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
41 Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
42 Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001 Sep;60(3):595-602.
43 Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
44 Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
45 Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer. 2004 Mar 20;109(2):167-73. doi: 10.1002/ijc.11720.
46 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
47 Estrogenic activities of Ginkgo biloba extracts. Life Sci. 2004 Jan 30;74(11):1325-35. doi: 10.1016/j.lfs.2003.06.045.
48 Tartrazine and sunset yellow are xenoestrogens in a new screening assay to identify modulators of human oestrogen receptor transcriptional activity. Toxicology. 2012 Aug 16;298(1-3):40-51. doi: 10.1016/j.tox.2012.04.014. Epub 2012 May 3.
49 Arsenic induces functional re-expression of estrogen receptor by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.
50 Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicol Sci. 2005 Feb;83(2):257-63.
51 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
52 Characterization of the weak estrogen receptor alpha agonistic activity of exemestane. Breast Cancer Res Treat. 2009 Aug;116(3):461-70. doi: 10.1007/s10549-008-0151-x. Epub 2008 Aug 3.
53 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
54 Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim Acta. 2001 Oct;312(1-2):213-9. doi: 10.1016/s0009-8981(01)00626-x.
55 Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
56 Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
57 EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
58 Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 2007 Aug 1;67(11):1152-62. doi: 10.1002/pros.20585.
59 Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
60 An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817.
61 Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
62 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
63 TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
64 Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
65 Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
66 Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
67 Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
68 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
69 Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.
70 A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
71 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
72 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
73 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.